By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – GenMark Diagnostics today reported a net loss of $5.4 million, or $.27 per share in the fourth quarter, compared to a net loss of $3.5 million, or $.30 per share, a year ago.
Registering provides access to this and other free content.
Already have an account?Login Now.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.